Guggenheim Doubles Tenax (TENX) PT, Names Stock Top Pick

Core Viewpoint - Tenax Therapeutics Inc (NASDAQ:TENX) is recognized as one of the best-performing micro-cap stocks in 2025, with Guggenheim raising its price target to $25 from $14, citing a unique market position targeting a large, untreated patient population [1][2]. Group 1: Financial and Operational Highlights - Guggenheim has confirmed that Tenax has successfully cleared its financial hurdles and secured enough capital to fund operations through major clinical milestones in 2026, designating it as a "Top Pick for 2026" [2]. - The company conducted a pre-planned statistical review of the first 150 patients in its LEVEL study, confirming that the trial is powered at over 90% to detect the drug's effectiveness, indicating sufficient patient numbers for valid results [3]. - Data variability was lower than initially feared, allowing the company to maintain sufficient statistical power without needing to increase enrollment, with a target of approximately 230 patients [4]. Group 2: Product Pipeline and Focus - Tenax Therapeutics is a specialty pharmaceutical company focused on developing and commercializing therapies for cardiovascular and pulmonary diseases, with key drug candidates including levosimendan for pulmonary hypertension and TNX-201 for angina [5].